116 results about "Immune microenvironment" patented technology

The invention discloses an application of bee venom lipid nanoparticles, which relates to the technical field of biological science and a pharmaceutical carrier. The bee venom lipid nanoparticles of the invention are composed of bee venom hybrid polypeptide and phospholipid and cholersteryl ester. The immune activation and anticancer agent prepared by the bee venom lipid nanoparticles is used fortargeting antigen presenting cells, and activates antigen presenting cells to improve the immune microenvironment, so as to generate a systemic immune response and inhibit tumor growth and metastasiseffect; the agent is also used to target and activate dendritic cells, macrophages, and B cells to inhibit the production of distant tumors; and the agent is also used to target hepatic sinusoidal endothelial cells and induce them to release a variety of immune factors to inhibit tumor liver metastasis. The immune activation and anticancer agent prepared by the bee venom lipid nanoparticle has notoxic and side effects, does not depend on the tumor type, and has good anti-tumor effect.

The invention belongs to the field of tissue engineering, and particularly relates to a bionic degradable artificial nerve conduit for regulating and controlling immune microenvironment and guiding regeneration by utilizing a topological structure. The bionic degradable artificial nerve conduit comprises a shell (1) and inner fibers (2), wherein the shell (1) adopts a first material with degradation time of 12-24 months; and the inner fibers (2) are made of a second material with the degradation time of 3-10 months. The bionic degradable artificial nerve conduit has the beneficial effects thatthe macrophages can be regulated and controlled by the internal fibers, so the macrophages are polarized into M2 phenotypes for promoting tissue regeneration, and nerve regeneration is further promoted; the degradation speed of the shell is matched with a nerve scar formation period, so infiltration of surrounding tissue is effectively prevented, and formation of scar tissue is avoided; and the shell is provided with pores, so nutrient exchange and substance transfer of nerve cells in the regeneration process are not influenced.

The invention discloses an application of a proteasome inhibitor in anti-cancer drugs. The proteasome inhibitor comprises Carfilzomib (carfilzomib), Bortezomib (bortezomib), MLN9708 (ixazomib), MG132and the like. The targeted cancer is a cancer in which macrophage polarization participates, i.e., a tumor in which the macrophage type is mainly M2 type in a tumor microenvironment, including a solidtumor and a hematologic tumor, and also including an in-situ cancer and a transplanted cancer. It is found through a large amount of creative work that the proteasome inhibitor converts M2 type TAM in the tumor immune microenvironment into M1 type TAM, thereby improving the tumor microenvironment, promoting the phagocytic effect of macrophages on tumor cells and increasing infiltration of immunecells on tumors to inhibit tumor growth.

The invention belongs to the field of clinical medicine, and relates to a model for predicting the curative effect of hepatocellular carcinoma immunotherapy based on 5 genes and a construction method thereof. The model for predicting the immunotherapy effect of hepatocellular carcinoma comprises five genes, namely lactic dehydrogenase A (LDHA), phosphatide phosphoramidate heterogeneous enzyme (PPAT), a bead fiber structural protein 1 (BFSP1), a nuclear receptor sub-fiber 0 group B member 1 (NR0B1) and 6-phosphatide-2-kinase / fructolase-2,6-diphosphatase 4 (PFPFB4). The invention also provides a construction method of the model for predicting the curative effect of hepatocellular carcinoma immunotherapy based on the 5 genes. Herein, the new immune microenvironment model based on 5 genes is established, so that the effect of a patient on HCC immunotherapy can be effectively predicted, and the 5 genes can be used as potential biomarkers to be clinically applied.

The invention discloses a construction method of a tumor immune microenvironment prediction model based on RNAseq. The method comprises the first step of determining 24 cell types related to the tumormicroenvironment; the second step of selecting 301 marker genes preferably according to the cell types obtained according to the above step; the third step of calculating the gene expression amount TPM using kallisto software, calculating the average expression amount of a corresponding marker gene of each cell type and then taking a log value as the relative abundance of the cell type. Accordingto the construction method, the average expression amount of the corresponding marker gene of each cell type is calculated, that is, the average value of a set of marker genes, and the result is relatively more stable and less affected by the relative error compared with calculation of the single marker gene.

The invention relates to the technical field of anti-tumor treatment drugs, in particular to application of beta-glucan combined with an anti-tumor drug in anti-tumor treatment. Beta-glucan is beta-glucan polysaccharide derived from yeast and comprises beta-1,3 / 1,6 glucan, and structurally, a yeast beta-glucan main chain is formed by connecting glucose monomers through beta-(1, 3) bonds, and a side chain is connected to the main chain by glucose through a beta-(1, 6) glycosidic bond; and beta-glucan and an antibody or a small molecule drug are applied in a combined mode, the anti-tumor effectis achieved by improving the tumor immune microenvironment, beta-glucan can promote natural immune effector cells to kill complement-conditioned tumor cells through a complement CR3 dependence mechanism, and multiple animal tumor models show that compared with any monotherapy, the situation that the beta-glucan and a complement activator or an anti-tumor antibody are combined for treatment can remarkably delay the tumor growth, and the total lifetime can be prolonged.

The invention discloses fibrin gel containing adriamycin-entrapped platelet exosome and PD-L1 monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of medicines, and compared with an adriamycin solution, the adriamycin-entrapped platelet exosome can be better combined with tumor cells, induce death of immunogenic tumor cells and promote anti-tumor immune response. Meanwhile, the blood platelet exosome loaded with adriamycin can enter blood circulation through damaged blood vessels, and tumor cells in circulation are tracked and removed. The aPD-L1 is released at the tumor site at the same time, so that a PD-1 / PD-L1 pathway can be blocked, and the tumor killing effect of cytotoxic T cells is recovered. The combination of the two strategies can trigger stronger T cell immune response, and obviously improves the tumor immune microenvironment. The method provided by the invention provides a new strategy and more choices for the combination of chemotherapy and immunotherapy, and meets the urgent demand on efficient preparations in clinic.

The invention relates to the technical field of biomedicine, in particular to an EGFP-Wnt2 fusion protein antigen, a Wnt2 monoclonal antibody and an application of a Wnt2 monoclonal antibody. The EGFP-Wnt2 fusion protein antigen is mainly a fusion protein of EGFP and a full-length amino acid sequence of a humanized Wnt2 signal-erasing peptide. The EGFP-Wnt2 fusion protein antigen comprises an EGFPamino acid sequence, a TEV restriction enzyme cutting site and a FLAG tag sequence, and the Wnt2 signal-erasing peptide full-length amino acid sequence, a 6* His tag sequence and an anti-Wnt2 monoclonal antibody can be used for inhibiting immune escape and growth of tumor cells. When the Wnt2 monoclonal antibody disclosed by the invention is combined with the human Wnt2 antigen secreted by cells,the promotion of the cell on the formation of an inhibitory immune microenvironment in a tumor is antagonized, and the immune escape and growth of the tumor cell are inhibited. The Wnt2 monoclonal antibody provided by the invention can be used in immune treatment of solid tumors such as esophageal squamous carcinoma, gastric cancer, pancreatic cancer, colorectal colon cancer, lung cancer, breastcancer, glioma, liver cancer and the like.

The present invention provides liposomes co-carrying CD73 antibody and doxorubicin and its preparation method and application, wherein, the liposomes co-carrying CD73 antibody and doxorubicin is a lipid core coated with doxorubicin, The CD73 antibody is modified outside the lipid core, and the CD73 antibody is modified on the surface of the lipid core by coupling to the phospholipid PEG active ester micelles. The liposomes co-carrying CD73 antibody and doxorubicin provided by the invention reduce the drug resistance and side effects of doxorubicin in the treatment of triple-negative breast cancer, improve the biodistribution of doxorubicin in the body, and increase the bioavailability , and reversed the immune microenvironment in the tumor of triple-negative breast cancer, turning it into a hot tumor, and achieved a better therapeutic effect on triple-negative breast cancer.

The invention belongs to the field of biological medicines, and relates to a dual-modified engineered bacterium and application thereof, in particular to an engineered bacterium externally coupled with an immune checkpoint inhibitor and internally coded with a tyrosinase gene, a pharmaceutical composition containing the dual-modified engineered bacterium and application of the pharmaceutical composition. Wherein the engineered bacterium is preferably escherichia coli. By utilizing the engineered bacteria, melanin expression and distribution which are controllable in space and time are obtained, melanin is similar to an inhibitor in distribution, and the melanin and the inhibitor are combined to enhance a dual-immune activation effect and synergistically reprogram a tumor immune microenvironment. The engineered bacterium can significantly inhibit tumor growth and prolong the lifetime by being singly used or combined with a conventional tumor treatment mode or medicine. The pharmaceutical composition containing the bacteria or the application of the pharmaceutical composition not only overcomes the difficult tumor inner barrier, but also has good permeability, and can uniformly and enduringly disperse the anti-tumor drug into the whole tumor.